Bibliografia
Messori A, Santarlasci B, Tripoli S, Vaiani M. Controvalore economico del farmaco e beneficio clinico: stato dell’arte della metodologia e applicazione di un algoritmo farmacoeconomico. PharmacoEconomics-Italian Research Articles 2003; 5: 53–67
Bross P, Nagamura F, Burke L, et al. Food and Drug Administration (FDA) experience with patient reported outcomes (PRO) and global quality of life (QOL) assessments in the approval of oncology drug products. Proc Am Soc Clin Oncol 2003; 22: abstract 2123
CPMP. Note for guidance of anticancer medicinal products in man. London, 2003. EMEA. Disponibile via URL all’indirizzo: http://www.emea.eu.int/pdfs/human/ewp/020595en.pdf
Szucs TD, Mantovani LG. The perspective of a pharmacoeconomic study: targeting for audiences. Pharm Res 1997; 35: 471–5
Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford; Oxford University Press, 1987
Bibliografia
Messori A, Santarlasci B, Trippoli S, Vaiani M. Controvalore economico del farmaco e beneficio clinico: stato dell’arte della metodologia e applicazione di un algoritmo farmacoecoonomico. Pharmacoeconomics-Italian Research Articles 2003; 5: 53–67
Messori A, Santarlasci B, Trippoli S, Vaiani M. Spending on statins. eBMJ http://bmj.com/cgi/eletters/327/7420/933-b#38400, 20 Oct 2003
Vacca F, Pelagotti F, Messori A. Cost effectiveness of statins in men vs women. eBMJ http://bmj.com/cgi/eletters/327/7420/933-b#39209, 30 Oct 2003
Messori A, Santarlasci B, Trippoli S, Vaiani M. “Polypill” to fight cardiovascular disease: cost effectiveness of statins for primary prevention of cardiovascular events is questionable (Letter). BMJ 2003; 327: 808–9.
Messori A, Santarlasci B, Trippoli S, Torricelli F. Orphan drugs in Europe: are we spending too much? eBMJ http://bmj.com/cgi/eletters/320/7245/1294#37030, 26 Sep 2003
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fattore, G., Chiroli, S., Mantovani, L.G. et al. Beneficio clinico e prezzo dei farmaci. Pharmacoeconomics-Ital-Res-Articles 6, 51–58 (2004). https://doi.org/10.1007/BF03320623
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03320623